Form 4: United Therapeutics Exec Trades Shares

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported transactions involving the acquisition and disposition of common stock on April 7, 2026, executed under a 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, engaged in a series of stock transactions on April 7, 2026.
• These transactions included the acquisition of 9,500 shares of common stock at $146.03 per share and the disposition of a significant number of shares through multiple sales at prices ranging from $556.89 to $569.74.
• The dispositions were part of a pre-arranged 10b5-1 trading plan adopted on November 7, 2025, which is set to continue until the exercise of 1,734,410 stock options expiring on March 17, 2027, or December 31, 2026, whichever comes first.
• Following these transactions, Rothblatt beneficially owns 40,513 shares of common stock directly, with additional holdings through a spouse, and various trusts.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, reflecting routine executive stock transactions under a pre-arranged plan rather than signaling a significant change in the company's fundamental outlook.

Positives

• The acquisition of 9,500 shares at a lower price point ($146.03) suggests a potential strategic investment or option exercise at a favorable valuation.
• The execution of trades under a 10b5-1 plan indicates a structured and pre-determined approach to stock transactions, often viewed positively for its adherence to compliance and avoidance of insider trading concerns.
• The reporting person retains a substantial number of shares (40,513 directly) and has significant indirect beneficial ownership, indicating continued commitment to the company.

Negatives

• A large volume of common stock was disposed of, with total sales amounting to tens of thousands of shares.
• The weighted average sale price across various transactions indicates a significant divestment at prices considerably higher than the acquisition price, suggesting profit-taking.

Risks

• The 10b5-1 plan has an expiration date of December 31, 2026, or upon exercise of 1,734,410 stock options, creating a defined window for future transactions.
• The plan's continuation is contingent on the exercise of stock options, which are set to expire on March 17, 2027, introducing a time-bound element to the ongoing trading strategy.

Future Outlook

The 10b5-1 trading plan is active and will continue until December 31, 2026, or until 1,734,410 stock options are exercised, whichever occurs first. These options expire on March 17, 2027.

Management Comments

• The exercise of stock options and sale of resulting shares was pursuant to a pre-arranged 10b5-1 trading plan.
• The reporting person undertakes to provide full information regarding the number of shares and prices at which transactions were effected upon request to the SEC staff, the issuer, or a security holder.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for reporting insider transactions. The use of a 10b5-1 plan by a high-level executive like a CEO is common practice to manage personal stock sales in a compliant manner, especially when dealing with significant option grants or portfolio diversification.

Stakeholder Impact

• Shareholders may observe the significant volume of shares sold by a key executive, which could be interpreted in various ways, though the 10b5-1 plan mitigates concerns about opportunistic trading.
• Employees holding stock options may note the executive's strategy for exercising and managing their equity compensation.

Next Steps

• The 10b5-1 trading plan will continue until its specified termination conditions are met.
• Further transactions may occur under the 10b5-1 plan until December 31, 2026, or the exercise of 1,734,410 stock options.

Key Dates

Keywords

Form 4, SEC Filing, United Therapeutics Corp, UTHR, Martine A. Rothblatt, Stock Options, 10b5-1 Plan, Insider Trading, Beneficial Ownership, Common Stock, Stock Transactions